Avidity Partners Management’s Karyopharm Therapeutics KPTI Stock Holding History

Avidity Partners Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.44M	Buy	927,482 +792,916	+589%	+$6.04M	0.69%	19
2025 Q4	$990K	Hold	134,566	–	–	0.29%	38
2025 Q3	$880K	Hold	134,566	–	–	0.2%	42
2025 Q2	$580K	Hold	134,566	–	–	0.12%	53
2025 Q1	$503K	Sell	134,566 -1	-0%	-$9	0.1%	64
2024 Q4	$1.37M	Hold	134,567	–	–	0.13%	61
2024 Q3	$1.68M	Hold	134,567	–	–	0.09%	78
2024 Q2	$1.75M	Sell	134,567 -418,671	-76%	-$6.93M	0.07%	81
2024 Q1	$12.5M	Hold	553,238	–	–	0.4%	65
2023 Q4	$7.18M	Hold	553,238	–	–	0.26%	64
2023 Q3	$11.1M	Sell	553,238 -4,769	-0.9%	-$107K	0.45%	64
2023 Q2	$15M	Sell	558,007 -84,254	-13%	-$3.63M	0.52%	64
2023 Q1	$37.5M	Hold	642,261	–	–	1.24%	32
2022 Q4	$32.8M	Buy	+642,261	New	+$44.5M	0.71%	41

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Avidity Partners Management's KPTI Position: Q1 2026 in Review

Avidity Partners Management increased its Karyopharm Therapeutics (KPTI) stake by 589% in Q1 2026, buying an estimated $6.04M and bringing the position to 927,482 shares worth $6.44M. The position accounts for 0.69% of the portfolio, ranked #19.

Avidity Partners Management first reported a position in KPTI in Q4 2022 and has held it in 14 quarters since. The position peaked at $37.5M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Avidity Partners Management held 927,482 shares of Karyopharm Therapeutics worth $6.44M as of Q1 2026.
Avidity Partners Management bought 792,916 Karyopharm Therapeutics shares in Q1 2026, an estimated $6.04M.
Karyopharm Therapeutics made up 0.69% of Avidity Partners Management's portfolio in Q1 2026, its #19 holding.
Avidity Partners Management first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 14 quarters since.
Avidity Partners Management's Karyopharm Therapeutics position peaked at $37.5M in Q1 2023.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.